Immunity to infection in IL-17-deficient mice and humans
about
IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A TherapiesA Dormant Microbial Component in the Development of PreeclampsiaTreatment challenges in the management of moderate-to-severe plaque psoriasis - role of secukinumabCancers Related to Immunodeficiencies: Update and PerspectivesPrimary immunodeficiencies underlying fungal infectionsIL-6 as a druggable target in psoriasis: focus on pustular variants.Innate-like and conventional T cell populations from hemodialyzed and kidney transplanted patients are equally compromisedCandida albicans commensalism in the gastrointestinal tract.Syk signaling in dendritic cells orchestrates innate resistance to systemic fungal infection.Caspase-1-independent interleukin-1β is required for clearance of Bordetella pertussis infections and whole-cell vaccine-mediated immunityInherited IL-17RC deficiency in patients with chronic mucocutaneous candidiasisSTAT3 is a critical cell-intrinsic regulator of human unconventional T cell numbers and functionOne Dose of Staphylococcus aureus 4C-Staph Vaccine Formulated with a Novel TLR7-Dependent Adjuvant Rapidly Protects Mice through Antibodies, Effector CD4+ T Cells, and IL-17A.Parasite Antigen-Specific Regulation of Th1, Th2, and Th17 Responses in Strongyloides stercoralis Infection.IL-17A promotes protective IgA responses and expression of other potential effectors against the lumen-dwelling enteric parasite Giardia.Novel nanoscale bacteriophage-based single-domain antibodies for the therapy of systemic infection caused by Candida albicans.Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis.Interleukin-17A Contributes to the Control of Streptococcus pyogenes Colonization and Inflammation of the Female Genital Tract.An Immunological Perspective on Neonatal Sepsis.Clinical features of Candidiasis in patients with inherited interleukin 12 receptor β1 deficiency.Controlled Mycobacterium tuberculosis infection in mice under treatment with anti-IL-17A or IL-17F antibodies, in contrast to TNFα neutralization.Chronic mucocutaneous candidiasis disease associated with inborn errors of IL-17 immunity.Candida albicans airway exposure primes the lung innate immune response against Pseudomonas aeruginosa infection through innate lymphoid cell recruitment and interleukin-22-associated mucosal responseMaking sense of the cause of Crohn's - a new look at an old disease.Simple diagnosis of STAT1 gain-of-function alleles in patients with chronic mucocutaneous candidiasisEmerging new roles of Th17 cells.Dysregulation in lung immunity - the protective and pathologic Th17 response in infection.Innate lymphoid cells in the defense against infections.Staphylococcus aureus Colonization: Modulation of Host Immune Response and Impact on Human Vaccine Design.The role of IL-17 in psoriasis.Protective immune responses to fungal infections.Infections from 7 Clinical Trials of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, in Patients with Moderate-to-Severe Psoriasis.Antifungal Immunological Defenses in Newborns.Activation strategies for invariant natural killer T cells.IL-17: overview and role in oral immunity and microbiome.Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A.Therapeutic Antibody-Induced Vascular Toxicity Due to Off-Target Activation of Nitric Oxide in Cynomolgus Monkeys.Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections.PD-L1 up-regulation restrains Th17 cell differentiation in STAT3 loss- and STAT1 gain-of-function patients.Antibody-Independent Function of Human B Cells Contributes to Antifungal T Cell Responses.
P2860
Q26830943-8C668442-A58E-477B-A2F1-C914172EDE50Q28069689-C41763F9-38C3-40A1-A54A-39D5F574A17BQ28069819-7BD71271-427D-4E29-865F-4AE60D395781Q28074182-CE9DE997-48C0-4E02-A78A-1F3A06AB299DQ33902831-58CA2FA4-AC7D-420B-AFA1-FCA80A262762Q34003280-0DC6E9EC-CBA6-41B7-94E4-CA8A8E052EA0Q34075522-091350F4-BC21-4CA3-818B-183EE356BFA6Q34492985-4117AD55-309D-4A10-8BC7-5DF449CC281BQ35208352-DE5FDBA7-84AB-4BAE-AB0A-9053C5A7E6DBQ35242597-68841C86-DB6E-4DB7-8262-BE2EED42B7ADQ35568424-BEAC889B-3403-4BFD-A0DF-A77BAB863593Q35671239-79F9FCDE-99E0-445F-851C-A1FDAE3E33C1Q35904895-5512BADA-6FD2-4F9A-A3F9-BC5D475740E8Q35988512-9C66AFD1-D26D-4257-82D0-DFE59F21391CQ35991614-AE377DA2-4157-46B6-BA60-E57A9E0B1D1FQ36112280-7A9EE910-42E9-414F-9EE3-885696A9B313Q36512728-CC2AC99D-FE10-412C-AA9D-03814F61194FQ36949520-CF1C17B9-DA5C-4167-9756-A101E9B58FDAQ37407684-5BD06446-E00B-436E-9394-DFEEC41E56FAQ37411703-4EC6570F-49BB-4F9C-BA7A-5E1891133116Q37420149-85A20178-D5EB-4CED-B5F3-7983F236B18AQ37538514-6399BAC5-6613-4817-8336-6D5ADFBF9B2CQ37548220-77235370-06F3-4603-8105-66E8EAC68BCDQ37577712-B8DD9117-A92B-4E5B-88AF-2AC4EB43B1FDQ37644982-81A105A4-B80F-4832-A5CC-0336C1A10248Q38040739-BC5E9E8C-CA7D-4ACB-9359-903AF91496E2Q38153014-B67A929F-CF0B-4254-AD28-066542002283Q38165175-BBF5532B-3BA9-487E-9D35-8D50319943E1Q38177271-B08EFDFC-A493-4000-9F85-86ABD4703FDCQ38189480-A01AEB1A-82D8-4FDA-AABC-2739BE095491Q38247209-A7A8079F-C607-4734-8E26-50A522CE677DQ38732809-045F8731-AB4D-48FE-AD86-EE1F18B7D007Q38865776-B0D5CD85-333E-45C0-8CF6-8F136A2D0702Q38908501-87B902D3-5788-40B2-8294-94E1181E36BEQ38986139-FFD90DDE-F0B9-4523-99E2-FFF787EABA31Q39796268-D1B2710B-1C67-49CA-8576-289C693BC118Q39966848-AC95DB16-F856-4B3F-91C2-BEC2A9915A94Q40068511-F86DE665-A8EC-4684-9E5E-A89A929D6BEFQ40134025-597F84A6-829E-42E4-8881-1332933C9040Q40302214-78E735D4-ED56-45EA-969D-C2A4DD362881
P2860
Immunity to infection in IL-17-deficient mice and humans
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunity to infection in IL-17-deficient mice and humans
@en
Immunity to infection in IL-17-deficient mice and humans.
@nl
type
label
Immunity to infection in IL-17-deficient mice and humans
@en
Immunity to infection in IL-17-deficient mice and humans.
@nl
prefLabel
Immunity to infection in IL-17-deficient mice and humans
@en
Immunity to infection in IL-17-deficient mice and humans.
@nl
P2860
P50
P356
P1476
Immunity to infection in IL-17-deficient mice and humans
@en
P2093
László Maródi
Sophie Cypowyj
P2860
P304
P356
10.1002/EJI.201242605
P407
P577
2012-09-01T00:00:00Z